This essay has been submitted by a student. This is not an example of the work written by our professional essay writers.
Abstract: Treatment of cancer cells with macromolecular chemotherapy is no longer a preferred choice of treatment. Progressive accumulation of oncogenic mutation in cancer cells leads to development of resistance towards efficacy of chemotherapeutics. Hence, currently efforts are focused on developing pharmaceutical peptides that act as antagonistics to the interacting motifs of important regulatory enzymes for instance DNA replication and repair process, recent use of cell penetrating peptides for development of cellular imaging and bimolecular delivery tools they are also considered as future agents for improving cancer chemotherapy. A major mechanism of cancer cells adapted resistance towards clinically used alkylating agents (cisplatin and carboplatin) is based on the effective removal of alkylated lesions in DNA via the elevated expression of DNA repair enzymes such as oxidative demethylase enzyme genes (human AlkB homologues). Use of peptide therapeutics has shown to exhibit high efficacy and low chemo toxicity. One of the recognized approaches for improving the efficacy of therapeutic potential is by blocking the interactive motifs between important cell cycle regulating enzymes by expression of peptides thereby increasing cellular cytotoxicity towards many cytotoxic agents. Thus peptide base therapeutics could be used to treat drug resistant cancer cells or delivery of the therapeutics to the target cancer cells.
Cancer is known to cause due to clonal expansion of a single founder cells due to alteration in DNA in the form of somatic mutations and epigenetic alterations were known to involve in development of cancer . One of the main obstacles over the current chemotherapy to cancer is development of multidrug resistance in advanced and metastatic solid tumors over the commonly used first line chemotherapeutics (Paclitaxel and docetaxel) of anthracycline based. Irrelevant usage of cancer therapeutics has lead to resistance towards systemic cancer therapies which is known to driven by intra tumoral genetic heterogeneity of tumor cells and genomic instability .
One of the important goals of a successful cancer treatment by chemotherapy is to deliver the cytostatic drug to the target tumor cell or tumor environment while leaving normal cells unaffected. However the use of these treatments is not always successful as accumulation of cytostatic drug towards the target is low compared with accumulation of cytostatic drug in normal tissues. One possible explanation for this is due the interstitial fluid pressure in solid tumors is higher than the normal tissues which lead to blockage of trans-capillary transport of chemotherapeutic drugs .
Prolonged use of the single chemotherapeutic agent leads to the development of resistance to multiple structural unrelated compounds known as Multidrug resistance (MDR). A common phenomenon of MDR phenotypic cancer cells is to pump the drugs over tumor cells mediated by ATP-dependent membrane transporter P-glycoproteins (P-gp). MDR appears to be increasing in various types of cancers for instance treatment of hepatoma with systemic treatment of anti tumor drug doxorubicin (Dox) has led to lower response rates as little as 10-20%. In addition to this p-glycoproteins in MDR tumor cells are now known to expel a broad range of anti cancer drugs and other functional related homologues termed as cross resistance .
In addition to the alterations of P-gp, enzymes which participate in DNA repair processes were also known to altered functions in breast cancer drug resistance. For instance reduced expression of a important DNA repair enzyme topoisomerase II genes and loss of DNA-miss match repair activity which normally contributes to the DNA repair from drugs cause double stranded breaks and alkylation damages contributes to the microsatellite instability, altogether known to associate with resistance in towards epipodophyllotoxins in breast cancer cells .
Thus chemotherapeutic potential of chemotherapy is decreased and increased dose of chemotherapy is related to increased toxic effects to normal cells. Hence, there is a significant need for new kind of molecules or therapeutics with low vulnerability to common drug resistance mechanisms for overall increased drug response rates and sustainability.
Based on the recent scientific progress into the cellular DNA repair regulations by important DNA replication involved enzymes such as Topoisomerase II, Proliferating Cells Nuclear Antigens (PCNA) (unpublished data) and also Receptor tyrosine kinases of the epidermal growth factor (EGF) receptor family have paved away to formulate new therapeutic approaches for anti cancer therapy. For instance designing of an inhibitory peptides that can block the important regulatory pathways associated with their protein interaction, peptides can also used as ligands to influence the function of target proteins .
Currently, conventional chemotherapeutics with chemical compounds were replaced with peptides that are selective towards the high affinity intracellular interactions are emerged as important molecular tools to manipulate important regulatory networks in cancer cells. Present situation of developing a new compound is replaced by derivatives of old classes by modifying them in their unique ways entered into current biopharmaceutical industry. It has been estimated that presently it takes 8.5 years of approval and clinical phases, and it costs over $559 million in order to reach approved drug to market .
Polypeptide antibiotics as therapeutics targets of microbial infection:
Innate immune response of the eukaryotic cells against bacterial cells in the form of effectors to defend them against microbes, these effectors are presently been considering and evaluating for polypeptide antibiotics. Over a period of time clinicians have used different kinds of polypeptide antibiotics, basically categorized into two different classes. Firstly there are cyclic decapeptides (loloatins and streptocidins) and secondly polymyxins category. Both these classes of peptides primarily acts by binding to the bacterial cell membrane, thereby altering their structural integrity through increasing water permeability finally leads to cell death of all gram-negative bacilli except the proteus group. Preliminary investigations by Felius L et.,al have shown that antimicrobial cyclic decapeptides not only posess antimicrobial activity but also have shown a promising candidates for cancer therapy. These cyclic decapeptides have exibited anti cancer activity through their effects on apoptosis (poly(ADP-ribose) polymerase (PARP) , induction of tumor suppressor and cell signaling proteins (p53 and ERK1/2) of cervical carcinoma cells .
Oncogenes as therapeutic agents:
Over the few years completion of human genome sequence and insight over cellular gene expression pathways has significant contributions over identification of wide variety of gene products which are differentially expressed in cancer and normal cells. Among them genetic mutations such as deletion of genes or point mutations and epigenetic alterations such as alterations in DNA methylation patterns are important factors behind the carcinogenesis . One of the hallmark characteristics exhibited by tumor cells is their autonomous cellular proliferations, tendency to invade other organs, genetic instability and their resistance towards apoptosis. In order to design better therapeutic potential we need to better understand the rate limiting steps of common genetic alterations in cancer cells. Systems biology facilitates to answer to these questions by understanding more about genes or gene products at the molecular level. Giuriato S postulated that inactivation of various oncogenes in different types of tumor cells lead to regression of tumor, suggesting that tumor cells require persistence expression of ontogenesis to maintain their transformed phenotype .
DNA repair proteins as therapeutic targets:
Environmental factors and somatic genetic mutations due to loss of heterozygosity during the process of cell division, cells have repair pathways that includes checkpoint controls for proof reading of any such errors by different repair proteins. When these mutations accumulates over a period of time leads to the cancer, patients with ataxia-telangiectasia (A-T) does not possess ATM kinase has inability to repair the broken ends caused by UV rays and chemotherapy. Some of these are manifested in case of patients with mutations in BRCA breast cancer genes that lack enzymes in repairing the stalling of replication forks by homologous and Non-homologous end joining. Despite polyploidity of cancer cells, it was found that polyploid cells (cancer cells) often employs a DNA repair programme that normally avoid their dependence on homologous recombination for repair thus attributed towards their uncontrolled cell divisions. Polyploidy cancer cells often express higher level of Mre11 and Rad 50 proteins in order to repair DNA damages quickly than homologous recombination .
The main focus of ongoing cancer research is to know how the insights of information about DNA repair pathway and damage sensing proteins might be translated into formulation of pro-diagnosis and better treatment. For therapeutic rationale, it is very important to understand the rate limiting and reversible alterations of DNA repair process for designing more promising drug targets in future.
A NOVEL APPROACH FOR USE OF PEPTIDES AS CANCER THERAPEUTICS:
Depending on the knowledge accumulated over the years of research on extensive study of DNA repair pathways and damage response cell signaling, new technologies are being developed in order to further extend the therapeutic application range. Among them designing of specific antagonistic for interacting motifs and specific inhibition of signaling enzymes are some of them. Over 16 years span, around 1111 cancer therapeutics have been entered into clinical study . All cancer therapeutics are designed to interfere with some of the vital functions of cancer cells, the general outcome is typically inhibition of cell proliferation or destruction of tumor cells. These therapeutics are classified into two major categories based on mode of action therapeutics on protein kinases which mainly inhibit one or more specific signaling pathway of cell cycle control or apoptotic pathway and other which interference with DNA replication procedures such as DNA topoisomareases. Conventional peptide therapeutics used acts as ligands to manipulate function of target protein by its specificity, and also acts as inhibitory proteins that function through allosterism and inhibitory properties .
Some of the targets for using therapeutic peptides act as important molecules, in few model systems they have selected based on their higher affinity intracellular interactions with specific target enzymes or structures and some of them are already used to manipulate important regulatory networks in cancer cells . Peptides which are discovered recently can be used as a mono therapy or in combination with clinical chemotherapeutic agents after discovery of individual peptides that inhibit their target function. Recent discovery of new small peptide, named as iRGD by Ruoslathi, seem to play an additional role of peptides are discovered in mouse known to act not only as therapeutics but also aids in penetration of other chemotherapeutic agents deep into the solid tumors.
Administration of iRGD peptide along with other common existing drugs have reported to significantly increase (From 15% to 80%) the amount of drug reached into a cancer cells. This will not only helps to kill effectively but also reduces drug dose to 1/3 of conventional usage. Since cancer cells are known to expel drugs, and also <10-15% is reached through them named as tumor penetrating peptides, since this peptide has the capability to bind specific ÎÂ±V integrins through a signature motif of arginine-glycine-aspartate, this motif acts as a ligand to neuropilin-1 receptor thereby increases the permeability of vascular tumor cells, this peptide has proven significance results not only towards increasing vascularity but also shown to penetrate when it is conjugated to the nano particles and monoclonal antibodies . As more data linking inhibitors and intracellular cross talk emerges pharmaceutical manipulation and design of new novel peptides would be an advantage. We are still far from being clear to understand how specific peptide ligand bind to their targets efficiently and specifically interfere with signaling functions and reach intracellular target sites without loss of their bioavailability?
DESIGNING OF INHIBITORY PEPTIDES
The designing of inhibiting peptides from natural binders are based on available high resolution crystallographic data and NMR experiments in order to study the interaction surface between target and its ligand. For instance the protein-protein interaction between matri cellular proteins TSP-1 (Thrombospondin-1) /FGF-2 (fibroblast growth factor) were exploited to design a inhibitory peptide, this kind of designing inhibitory peptides has drawn a considerable interest over few years. TSP-1 participates in inhibition of angiogenesis which is mediated by its interactions with CD36, integrins receptors in endothelial cells . The interaction between TSP-1 with angiogenic factors such as FGF-2 and PDGF might be exploited for designing a therapeutic intervention through their mechanism of angiogenesis regulation. Thus inhibitory peptide might be active in metronomic chemotherapy where frequent administration of lower doses of chemotherapy is proposed to optimize the overall anti angiogenic property of chemotherapeutics . These finding may indicate inhibitory peptide endogenous domains with high affinity can be used without screening of peptide libraries.
The main difference between natural binders and designed inhibitory peptides is not known. Knowledge of the target protein structure or its interface of natural partner is unknown. These peptides were selected based on random sequence identity synthetic peptide library. These random peptide libraries generate inserts with 12-20 amino acids long, thus generating high probability of these specific binders to predetermined targets known as peptide aptamers (PAs). PAs are small and conceptually similar to antibodies and they are isolated by yeast-two hybrid screening of large PAs library that consists of random peptide inserts against a target protein. This selected PAs in yeast cells allow us to identify interactors in mammalian cells. scientists are able to isolate various peptides which inhibits cancer related intracellular proteins involved in cell cycle progression (CDK1), cell signaling ( RAS) and viral oncoproteins such as HPV16-E6 & E7) by this method . these peptide aptamers have shown excellent anti-tumor effects and also more reliable over pleiotropic effects of current RNA interference techniques existing for cancer treatment, thus opening its wide usefulness in usage as therapeutic agents .
MODE OF DELIVERY OF PEPTIDE THERAPEUTICS:
conventional peptide used so far exert their action on cell surface by inducing or inhibiting one or multiple signal transduction pathways, with the knowledge acquired over a time period have allowed to design peptides that deploy them intracellular as cytosolic or nuclear signaling modulators. In order to perform first peptides need to be internalized.
Peptide Conjugated Liposomes:
One of the recognized strategies to improve overall therapeutic effectiveness of existing anti cancer cytostatic drug delivery is encapsulating the drugs into targeting liposomes, which bind to tumor specific cell surface receptors. .
Protein Transduction Domains (PTDs)
Delivery of bioactive peptides across blood brain barrier is restricted to 600 Da. currently, efficient modes delivery of therapeutic compounds was achieved by fusion of therapeutic peptides with short peptide sequences called PTDs. They have shown to be a promising tool for rapid translocation into nucleus for instance peptides that combines RGD sequence with a peptidic ligand for a transmembrane receptor neuropilin-1 (NRP-1) aids in penetration of drug into tumor .
Figure 1: Diagram of molecular mechanism of iRGD driven endocytic pathway, the therapeutic peptide here with RGD sequence interacts with tumor cells expressing ÎÂ±V integrins were aimed to block the PCNA interacting protein (PIP box) leads to the inhibition of interaction of PCNA with other important physiological pathways.
Table 1: Selected therapeutic peptides currently being developed
Information was obtained from the http://www.clinicaltrails.gov
EMA, European Medicine Agency
CHALLENGES FOR IN VIVO USE OF PEPTIDE THERAPEUTICS:
One of the fundamental problem using therapeutic peptides against cancer is their stability in In vivo conditions against serum and tissue peptidases (proteases). it seems to be retractable to increase resistance of these peptide drugs by modification (acetylation and amidation) of N and C-terminus of the peptides respectively replacement of the amino acids at the predicted cleavage sites with D-amino acids, this mode of designing and modification of peptide have shown to improve stability of a recently discovered glucagon like peptide GLP-1-(7-34)-amide which is developed as a treatment for type II diabetes. This peptide has shown to be more stable in presence of an endogenous proteases from minutes to at least two hours at the same time retaining its biological activity .
One of the potential problem of using peptide therapeutics is their ability to provoke immunogenicity of host system, as human immune cells have some receptors such as TLRs for sequence specific peptide patterns of foreign peptides this problem has been approached by cyclization of linear peptides by head to tail cyclization linking their N and C-terminus of polypeptide sequence and PEGylation .
Other important problem by use of peptides therapeutics is their bioavailability, due to their smaller molecular masses often renders them to expel from the circulatory system by renal clearance. This problem can overcome by addition of these therapeutic peptides by attaching with polyethylene glycol (PEG) moities by increasing overall molecular mass, for example PEG-Intron and Pegasys, both are used in the treatment of hepatitis C infections have shown to be a good clinical and pharmacokinetic profiles .
CONCLUDING REMARKS AND FUTURE PERSPECTIVES
One of the most important goals of current oncology research is to develop a highly specific anti cancer therapeutics that can discriminate between normal and tumor cells. For instance, recent evidence of use on tumor targeting by use of peptide that combines the RGD sequence with peptidic ligand for a transmembrane receptor neutropilin-1 has not only helped to selective tumor vascular targeting but also facilitates the penetration of drug into tumors. The recent data from Rusolathi laboratory suggested that first clinical studies on humans with iRGD are being carried out in order to understand the iRGD peptide binds NRP1 and that internalization of this receptor may stimulate cellular penetration of drug conjugated with this peptide sequence .
Some of the short peptides are key players or ligand induced gene expressions and other physiological responses. Currently pharmacological manipulation of the peptides with intracellular transport of chemotherapeutic drugs is a promising option to treat chemotherapy resistant tumors. Moreover, the binding of these peptides with bait proteins of interest might inhibit the complex cross talk of downstream signaling pathways, such as DNA damage sensing and repair proteins, which lead to constant loss of damages response proteins and better understanding of molecular pharmacological aspects of peptides, together with the information of high throughput screening of peptides by phage systems will soon lead to discovery of a new era of peptide-based therapeutics, including current protein transduction domain (PTD)and integrin binding peptide therapeutics for intracellular targets, which will drive major clinical benefits for cancer patients. Consequently, minimizing the risk for normal cells can provide rational basis of cancer tailored treatments.